Anti-Mouse IL-1R (CD121a) [Clone JAMA-147] — Purified in vivo GOLD™ Functional Grade

Clone JAMA-147 is widely used in vivo in mice to block IL-1 receptor type 1 (IL-1R1; CD121a) signaling, thereby functionally inhibiting interleukin-1 (IL-1)–dependent immune responses. Its primary application is the experimental modulation of immune and inflammatory pathways mediated by IL-1.

Key in vivo applications include:

• IL-1R blockade: JAMA-147 is used to prevent the binding of IL-1 (both IL-1α and IL-1β) to its receptor, thereby suppressing all downstream biological effects of IL-1, such as inflammation, fever, and leukocyte recruitment.
• Modeling and dissecting inflammatory diseases: By blocking IL-1R1, JAMA-147 facilitates the study of the role of IL-1 signaling in disease models of autoimmunity, infection, skin inflammation, and other immune-mediated pathologies.
• Studying cell-type-specific contributions: Since IL-1R1 is expressed on a range of cell types (T cells, dendritic cells, fibroblasts, epithelial cells, vascular endothelial cells, neural cells), JAMA-147 enables researchers to probe the function of IL-1 responses in diverse tissues in vivo.
• Testing therapeutic approaches: The antibody can be used to assess the therapeutic potential of IL-1 pathway blockade in preclinical models, supporting the development of anti-inflammatory drugs.

Additional context:

• JAMA-147 is a hamster monoclonal antibody, often administered systemically (e.g., by intraperitoneal or intravenous injection) in murine models.
• According to supplier datasheets and published literature, recommended use cases are both in vivo and in vitro blockade of IL-1R1.
• The blockade is specific to mouse IL-1R1 and has been validated for inhibition of IL-1–mediated effects such as cytokine production, leukocyte migration, and tissue swelling.

In summary, JAMA-147 is the standard tool for in vivo neutralization of IL-1 signaling in mouse models, providing a method to modulate and study inflammatory and immune responses mediated by this crucial cytokine pathway.

Other commonly used antibodies and proteins with JAMA-147 in the literature primarily include other monoclonal antibodies against mouse IL-1 receptor (CD121a) and antibodies targeting interleukin-1 (IL-1) itself.

Key examples include:

• JAMA-83: Recognizes a distinct epitope on type I IL-1 receptor and is frequently used alongside JAMA-147 for comparative or combinatorial studies.
• JAMA-84: Recognizes another distinct epitope on the same receptor, often co-used for epitope mapping, functional inhibition, and binding competition studies.
• JAMA-110: Targets a separate epitope from JAMA-147, used for multifaceted analyses of receptor function and blocking activity.
• M15 and 35F5: Earlier generation rat monoclonal antibodies specific for murine type I IL-1 receptor, used to benchmark JAMA-147’s inhibitory potency and specificity.

Additionally, antibodies against IL-1α and IL-1β are sometimes pooled with anti-IL-1R antibodies, including JAMA-147, to achieve broad blockade of IL-1 signaling in functional studies.

These combinations are routinely applied in:

• Competition and epitope mapping assays
• Neutralization or inhibition studies
• In vivo functional blockades of IL-1 activity

JAMA-147 is most effective when its unique binding specificity is combined with antibodies targeting alternate IL-1R epitopes or the ligand itself, providing a comprehensive blockade of the IL-1 signaling axis.

The key findings from the citations of clone JAMA-147 in scientific literature primarily relate to its application as a monoclonal antibody targeting mouse interleukin-1 receptor type 1 (IL-1R1), also known as CD121a. This antibody is used for various immunological studies, particularly in the context of inflammation and antiviral T cell responses. Here are some of the main uses and findings:

1. IL-1 Binding Prevention: Clone JAMA-147 prevents IL-1 from binding to the type I IL-1 receptor, which is crucial for mediating biological responses to IL-1α and IL-1β. This blocking capability is essential for studying the role of IL-1 in immune responses and inflammation.

2. In Vivo and In Vitro Applications: The antibody is used both in vivo and in vitro for IL-1R1 blockade. It is recommended for functional assays and receptor blocking experiments, highlighting its versatility in different research settings.

3. Expression on Multiple Cell Types: The IL-1 receptor type I is expressed on various cell types, including T cells, thymocytes, dendritic cells, fibroblasts, vascular endothelial cells, epithelial cells, and neural cells. This broad expression profile makes the JAMA-147 antibody a valuable tool for studying IL-1R1 in different cellular contexts.

4. Immune Response Studies: The antibody has been cited in studies examining immune responses, such as those involving neutrophils and other immune cells, contributing to a deeper understanding of IL-1's role in immune modulation.

These findings collectively underscore the significance of clone JAMA-147 in unraveling the complex roles of IL-1R1 in immunology and inflammation.

Clone JAMA-147 is a monoclonal antibody against mouse IL-1 receptor (CD121a), used primarily for IL-1 blockade in research settings. The dosing regimens for this clone can vary depending on the specific experimental model or research question. Here’s a general overview of how it might be used across different mouse models:

1. Dose and Administration:

   • Intraperitoneal (i.p.) Administration: The typical dose for clone JAMA-147 is a single administration of 4 mg/kg, given intraperitoneally. This method is commonly used in mouse studies to block IL-1 receptor activity.

2. Frequency of Administration:

   • The frequency can vary based on the study design. For some studies, a single dose might be sufficient, while others may require repeated doses, such as every other day, depending on the experimental design and the duration of the study.

3. Experimental Models:

   • Cancer Models: In cancer research, IL-1 blockade with clone JAMA-147 might be part of a combination therapy to evaluate its effects on tumor growth or treatment outcomes.
   • Inflammatory Models: This antibody is used to study the role of IL-1 in inflammation. Different models of inflammation may require different dosing schedules depending on the progression of the disease and the specific inflammatory pathways being studied.

4. Mouse Strains and Age:

   • The dosing regimen might need adjustments based on the mouse strain or age, as these factors can influence the immune response and drug pharmacokinetics. However, specific data on these variations is not detailed in the available literature.

In summary, while the standard dosing regimen for clone JAMA-147 in mouse models is typically a 4 mg/kg i.p. dose, adjustments may be necessary depending on the specific research question, experimental model, and desired duration of IL-1 blockade.